To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

June 28, 2019___

Today's Rundown

Featured Story

Adaptimmune CEO Noble to retire, CFO Rawcliffe steps up to the plate

Adaptimmune Chief Financial Officer Adrian Rawcliffe will take over in September when CEO and co-founder James Noble retires. The T-cell therapy specialist is now on the hunt for a new CFO.

Top Stories

Carrick hires ex-Tesaro CFO, shifts focus toward U.S. 

Carrick Therapeutics is shifting its center of gravity toward the U.S. The Anglo-Irish cancer biotech has appointed ex-Tesaro CFO Tim Pearson to lead the company from its new site in Boston.

Sierra doubles down on ex-Gilead drug, deprioritizes other assets

Sierra Oncology is betting its future on the phase 3 myelofibrosis drug it picked up from Gilead for a knockdown price. The JAK 1/2 inhibitor underwhelmed in the clinic at Gilead but Sierra has decided to focus its resources on the drug, leading it to search for non-dilutive ways to fund other assets.

[Sponsored] Frontage Holdings Corporation Celebrates a Successful Initial Public Offering on the HKEx

Frontage is Growing to Meet All Your Needs!

Treating pancreatic cancer by starving tumor cells

A research team at Sanford Burnham Prebys Medical Discovery Institute has offered fresh insights into how to starve tumor cells of nutrients, pointing to a possible way of developing new drugs to treat pancreatic cancer.

EuroBiotech Report—Sanifit bags €55M, LifeArc backs Kymab, Modag A round, Evotec and Verona

In this week's EuroBiotech Report, Sanifit bags €55 million, LifeArc backs Kymab and Modag raises €12 million A round. 

FiercePharmaAsia—Daiichi, Glenmark FDA refusals; Takeda U.S. HQ move; JLABS Shanghai opening

The FDA rejected Daiichi Sankyo's blood cancer drug quizarinib and Glenmark's rhinitis nasal spray Ryaltris. Takeda set a deadline for its U.S. headquarters move from Chicago to Boston. JLABS launched a Shanghai chapter with 31 startups. And more.

Chutes & Ladders—Frontier Medicines launches with biotech vet as CEO

Frontier Medicines is launching with $67 million and a biotech vet as CEO; after being snapped up by Alexion, Syntimmune's CEO is joining MorphoSys; and Recursion has named a Theravance veteran as CSO. Those moves plus more hirings, firings and retirings throughout the industry.

Resources

[Whitepaper] The essential guide to managing laboratory samples

This Essential Guide to Managing Laboratory Samples is a three-part piece exploring common problems experienced in the management of samples and how, for any scale of operation, significant efficiency and accuracy benefits can be gained using dedicated sample management software.

[Whitepaper] Satisfying GxP Requirements Using the Internet of Things (IoT)

How can the Internet of Things (IoT) enable you to meet GxP?

[Whitepaper] Managing Comorbidities in Type 2 Diabetes – Real World Evidence for Change

Patients living with diabetes deserve better – Real-World Evidence for effecting/realizing change in the management of type 2 diabetes and cardiovascular/renal comorbidities.

[Webinar] Why do US sponsors come to Russia? New options for clinical trials.

Fast and cost-efficient patient-enrollment,100% success strategy for obtaining a CTA, unified market authorization across the EEU countries. Find out the key compelling reasons to conduct studies in Russia.

[Whitepaper] Agile Competitive Intelligence Strategies For Healthcare

What is agile competitive intelligence, and how can it help take market research to the next level?

[POCKET GUIDE] Reference and Literature Management Made Easy

Get 5 quick tips for faster research and better results!

[Report] Precision medicine from concept to clinic

In this publication, Blue Latitude Health maps the journey of stakeholders impacted by the rise of precision medicine today. Download the report.

[Whitepaper] Flow Chemistry: A Scale-Up Solution for Modern API Development & Manufacturing

Increase Safety & Flexibility with Flow Chemistry

[On-Demand Webinar] Lessons Learned Implementing an End-to-End RIM Solution

IONIS shares best practices for implementing an end-to-end RIM solution in this on-demand webinar. Watch now.

[Whitepaper] Site-specific, Patient-centered and Whip-smart: Enrollment Assistants Adapt to a Shifting Landscape

Increasingly complex clinical trials place a tremendous burden on study sites, exacerbating already-troubling recruitment and enrollment issues. Overwhelmed, many sites may not be up to the task or have the appropriate infrastructure, creating costly delays that keep new therapies from patients.

[Case Study] Clinical Supply Management

Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study.

[Video] Demand Led Services and Clinical Supply Efficiency

Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels.

[eBook] Strategies for Efficient Clinical Supply Management and Forecasting

Download the eBook to explore a proactive approach for clinical supply management.

Events